Attached files
| file | filename |
|---|---|
| EX-32 - EXHIBIT 32 - ACURA PHARMACEUTICALS, INC | tm211138d1_ex32.htm |
| EX-31.2 - EXHIBIT 31.2 - ACURA PHARMACEUTICALS, INC | tm211138d1_ex31-2.htm |
| EX-31.1 - EXHIBIT 31.1 - ACURA PHARMACEUTICALS, INC | tm211138d1_ex31-1.htm |
| EX-10.53 - EXHIBIT 10.53 - ACURA PHARMACEUTICALS, INC | tm211138d1_ex10-53.htm |
| 10-K - FORM 10-K - ACURA PHARMACEUTICALS, INC | tm211138d1_10k.htm |
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
Acura Pharmaceuticals, Inc.
Palatine, Illinois
We hereby consent to the incorporation by reference in the Registration Statements on Form S-¬3 (Nos. 333-210039, 333-187075 and 333-146416) and Form S-8 (Nos. 333-221645, 333-213017, 333-195612, and 333-151620) of Acura Pharmaceuticals, Inc. of our report dated March 31, 2021, relating to the consolidated financial statements which appears in this Form 10-K. Our report contains an explanatory paragraph regarding the Company’s ability to continue as a going concern.
| /s/ BDO USA, LLP | |
| Chicago, Illinois | |
| March 31, 2021 |